Linked Life Data

17716681

Source:http://linkedlifedata.com/resource/pubmed/id/17716681

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17716681rdf:typepubmed:Citationlld:pubmed
pubmed-article:17716681lifeskim:mentionsumls-concept:C0524984lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C1823153lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C1514468lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C0302189lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C0175659lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C0349674lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C1705241lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C0439097lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C2349976lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C1552644lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C1547348lld:lifeskim
pubmed-article:17716681lifeskim:mentionsumls-concept:C0222045lld:lifeskim
pubmed-article:17716681pubmed:issue1-2lld:pubmed
pubmed-article:17716681pubmed:dateCreated2007-9-10lld:pubmed
pubmed-article:17716681pubmed:abstractTextgamma9delta2 T lymphocytes are non-conventional lymphocytes presenting a direct cytotoxic effect against a broad range of tumour targets. These cells also secrete inflammatory cytokines that can boost the other components of the immune system. In contrast to conventional CD8(+) T cells, the cytotoxic effect of gamma9delta2 T lymphocytes does not depend on the expression of major histocompatibility complex molecules by target tumour cells. INNACELL gammadeltatrade mark is a cell therapy product obtained by ex vivo amplification of mononuclear cells. The stimulation is achieved by a specific synthetic agonist of gamma9delta2 T lymphocytes, bromohydrin pyrophosphate (BrHPP). After a single stimulation with BrHPP, gamma9delta2 T lymphocytes are expanded for 2 weeks in a closed system in culture medium with interleukin-2 (IL-2). On day 15, cells are washed and harvested in 4% human serum albumin. In this manufacturing process, the total cell population is expanded by approximately 10-fold and gamma9delta2 T lymphocytes undergo a specific 1000-fold expansion, corresponding to a gamma9delta2 T lymphocyte enrichment of more than 70% at the end of the culture. This manufacturing process is much simpler than most current cellular therapy approaches using conventional CD8(+) T-cell lines or clones: there is no final or initial separation, no purification step and no use of feeder cells; the specific T-cell receptor-mediated signal provided by BrHPP is sufficient to trigger the IL-2-dependent expansion of the gamma9delta2 subset, which then becomes predominant in the cell culture in large amounts.lld:pubmed
pubmed-article:17716681pubmed:languageenglld:pubmed
pubmed-article:17716681pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17716681pubmed:citationSubsetIMlld:pubmed
pubmed-article:17716681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17716681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17716681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17716681pubmed:statusMEDLINElld:pubmed
pubmed-article:17716681pubmed:monthSeplld:pubmed
pubmed-article:17716681pubmed:issn0022-1759lld:pubmed
pubmed-article:17716681pubmed:authorpubmed-author:DrenoBrigitte...lld:pubmed
pubmed-article:17716681pubmed:authorpubmed-author:TiollierJérôm...lld:pubmed
pubmed-article:17716681pubmed:authorpubmed-author:LaplaceCather...lld:pubmed
pubmed-article:17716681pubmed:authorpubmed-author:BercegeaySylv...lld:pubmed
pubmed-article:17716681pubmed:authorpubmed-author:CassidaniusAl...lld:pubmed
pubmed-article:17716681pubmed:authorpubmed-author:TenaudIsabell...lld:pubmed
pubmed-article:17716681pubmed:authorpubmed-author:SalotSamuelSlld:pubmed
pubmed-article:17716681pubmed:authorpubmed-author:SaïaghSorayaSlld:pubmed
pubmed-article:17716681pubmed:authorpubmed-author:RomagneFranço...lld:pubmed
pubmed-article:17716681pubmed:issnTypePrintlld:pubmed
pubmed-article:17716681pubmed:day30lld:pubmed
pubmed-article:17716681pubmed:volume326lld:pubmed
pubmed-article:17716681pubmed:ownerNLMlld:pubmed
pubmed-article:17716681pubmed:authorsCompleteYlld:pubmed
pubmed-article:17716681pubmed:pagination63-75lld:pubmed
pubmed-article:17716681pubmed:meshHeadingpubmed-meshheading:17716681...lld:pubmed
pubmed-article:17716681pubmed:meshHeadingpubmed-meshheading:17716681...lld:pubmed
pubmed-article:17716681pubmed:meshHeadingpubmed-meshheading:17716681...lld:pubmed
pubmed-article:17716681pubmed:meshHeadingpubmed-meshheading:17716681...lld:pubmed
pubmed-article:17716681pubmed:meshHeadingpubmed-meshheading:17716681...lld:pubmed
pubmed-article:17716681pubmed:meshHeadingpubmed-meshheading:17716681...lld:pubmed
pubmed-article:17716681pubmed:meshHeadingpubmed-meshheading:17716681...lld:pubmed
pubmed-article:17716681pubmed:meshHeadingpubmed-meshheading:17716681...lld:pubmed
pubmed-article:17716681pubmed:meshHeadingpubmed-meshheading:17716681...lld:pubmed
pubmed-article:17716681pubmed:year2007lld:pubmed
pubmed-article:17716681pubmed:articleTitleLarge scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product.lld:pubmed
pubmed-article:17716681pubmed:affiliationInnate Pharma, 119-121 Ancien chemin de Cassis, 13009 Marseille, France. samuel.salot@innate-pharma.frlld:pubmed
pubmed-article:17716681pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17716681pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:17716681pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:17716681pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17716681lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17716681lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17716681lld:pubmed